23:51:25 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning EXPRS2 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 Årsstämma 2023
2023-05-16 Kvartalsrapport 2023-Q1
2023-03-23 Extra Bolagsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-07 Bokslutskommuniké 2017
2017-11-30 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-04-19 Extra Bolagsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag som har en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
2020-09-29 23:00:47

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW.

Hørsholm, Denmark, September 29, 2020 - the Extraordinary General Meeting ("EGM") of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") resolved on September 23, 2020 to carry out a share issue with preferential rights for the Company's existing shareholders including warrants (the "Offering"). Upon full subscription in the Offering, the Company will receive approx. SEK 131 million. If the warrants are exercised in full, the Company will additionally receive up to approx. SEK 85 million before deduction of costs related to the Offering. The board of directors of ExpreS2ion has in connection with the Offering, and prior to the subscription period that commences on 5 October 2020, prepared a prospectus which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "SFSA").

Publication of the prospectus

For complete information about the Offering, please refer to the prospectus that has been prepared by the Company and that today has been approved by the SFSA. The prospectus is available on ExpreS[2]ion's website (www.expres2ionbio.com) and Arctic Securities website (www.arctic.com/secse) and will also be available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/). The prospectus will be passported to Denmark and thus also available for Danish investors.

The prospectus is prepared as an EU-Growth prospectus in accordance with article 15 in the Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The prospectus has been approved by the SFSA, which is the Swedish competent authority in accordance with the Prospectus Regulation, in accordance with article 20 in the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of ExpreS[2]ion or as an endorsement of the quality of the shares that are the subject of the prospectus and does not indicate that the SFSA guarantees that the facts in the prospectus are correct or complete. Investors should make their own assessment as to the suitability of investing in the Offering.

Application forms will be available on the Company's and Arctic Securtities website respectively.

Timetable for the Offering

Last day of trading in shares September 29, 2020
including right to receive Unit
rights
First day of trading in shares September 30, 2020
excluding right to receive Unit
rights
Prospectus published (Denmark) Around September 30, 2020
Record date for participation in October 1, 2020
the Offering
Subscription period October 5 - October 19, 2020
Trading in Unit rights October 5 - October 15, 2020
Trading in BTUs (Paid subscribed October 5, 2020 - until the Offering is
Units) registered with  the Swedish Companies
Registration Office (Sw. Bolagsverket)
Announcement of final outcome in Around October 26, 2020
the Offering

Advisors

Arctic Securities AS, filial Sverige and Translution Capital ApS act as financial advisors to the Company in connection with the Offering. Arctic Securities is the Company's issuing agent whereas Baker Mckenzie is the Company's legal advisor in connection with the Offering.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se